Kestra Medical Technologies (KMTS) Depreciation & Amortization (CF) (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 5.03% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $8.2 million (down 14.68% YoY) and the FY2025 annual result came in at $8.0 million, down 31.07% from the prior year.
• Depreciation & Amortization (CF) slipped to $2.0 million in Q1 2026 per KMTS's latest filing, from $2.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.5 million in Q2 2024 and bottomed at $1.8 million in Q2 2025.
• The 3-year median for Depreciation & Amortization (CF) is $2.0 million (2025), against an average of $2.4 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 26.97% in 2025, while the deepest fall reached 47.57% in 2025.
• Tracing KMTS's Depreciation & Amortization (CF) over 3 years: stood at $1.9 million in 2024, then grew by 26.97% to $2.4 million in 2025, then retreated by 16.43% to $2.0 million in 2026.
• Per Business Quant, the three latest KMTS Depreciation & Amortization (CF) figures stand at $2.0 million (Q1 2026), $2.4 million (Q4 2025), and $2.0 million (Q3 2025).

Peer Comparison